RxDoctor Payments Data

Igor Porotov, MD

Neurology · Blue Bell, PANPI 1306945613

Payments from drug & device makers

$1,111in general payments, 2019–2025

Across 73 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$186
  • Biogen$175
  • AbbVie$172
  • Sanofi$150
  • Argenx US, Inc.$139
  • CSL Behring$80
  • plus $210 from 9 others

What the payments were for

  • Speaking & faculty fees$353%
  • Food & beverage$1,07697%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,111 in reported general payments places this provider in the 50th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$116,708
Medicare patients
459
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab13$333,795
Kesimpta PenOfatumumab19$203,208
CopaxoneGlatiramer Acetate20$114,921
VumerityDiroximel Fumarate13$112,331
Avonex (4 Pack)Interferon Beta-1a13$107,456
Teriflunomide11$68,518
Nurtec OdtRimegepant Sulfate16$27,460
Ajovy AutoinjectorFremanezumab-Vfrm19$19,669
UbrelvyUbrogepant19$19,084
QuliptaAtogepant14$14,781
Depakote ErDivalproex Sodium13$5,876
Levetiracetam92$4,130
Carbidopa-LevodopaCarbidopa/Levodopa134$3,444
Carbidopa-Levodopa ErCarbidopa/Levodopa28$3,391
AmantadineAmantadine Hcl50$2,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Avonex (4 Pack)$175$219,78726 claims
AbbVieUbrelvy, Qulipta$172$33,86533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Blue Bell

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →